Two separate lines of pancreatic cancer research reported actionable advances. A University of Pennsylvania–led preclinical study demonstrated that early intervention with KRAS inhibitors can intercept microscopic precancerous lesions, blocking progression to invasive pancreatic ductal adenocarcinoma (PDAC) in animal models. The result suggests a window for chemopreventive or early‑interception strategies targeting KRAS‑driven neoplasia. Separately, researchers developing a senolytic approach reported preclinical efficacy in PDAC models by targeting therapy‑induced or tumor‑associated senescent cells to alter the tumor microenvironment and sensitize tumors to treatment. Both studies, published in high‑impact journals, outline complementary strategies—molecular interception of KRAS‑driven lesions and microenvironmental remodeling via senolytics—that could reshape prevention and treatment paradigms for pancreatic cancer, a cancer with poor prognosis and limited therapeutic options.